Clinical trials are foundational to developing innovative, life-saving treatments and cures for patients. For developers of cell and gene therapy (CGTx) products, the path to clinical success is fraught with vast and complex challenges. The CGTx field is becoming more crowded, with increased clinical trial volume and an influx of less-experienced sponsors contributing to an increase in clinical holds in the category. Such challenges intensify the pressure to succeed in a fiercely competitive environment.
This white paper is based on a panel discussion hosted by Precision ADVANCE and Endpoints News featuring experts in the complexities of CGTx clinical development. Moderated by Teresa Pokladowski, Regional Vice President of Clinical Business Solutions, North America at Precision for Medicine, the panel included the following experts
- Dawn Buchanan, Vice President, Clinical Operations, Affyimmune Therapeutics
- Suma Krishnan, President, Research and Development, Krystal Biotech, Inc.
- Kinnari Patel, President and Chief Operating Officer, Rocket Pharmaceuticals Inc.
- Ramona Repaczki-Jones, Executive Director, Treatment Center Operations, Iovance Biotherapeutics
